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Abstract—The authentic standard PBB3 and its precursor N-desmethyl-PBB3 as well as TBS-protected N-desmethyl-PBB3 precursor for 
radiolabeling were synthesized from 5-bromo-2-nitropyridine, acrolein diethyl acetal, 6-methoxy-2-methylbenzothiazole, and 
diethylchlorophosphate with overall chemical yield 1% in six steps, 2% in five steps, and 1% in six steps, respectively. [11C]PBB3 was 
prepared from either desmethyl-PBB3 or TBS-protected desmethyl-PBB3 with [11C]CH3OTf through N-[
11C]methylation and isolated by
HPLC combined with SPE in 20-25% and 15-20% radiochemical yield, respectively, based on [11C]CO2 and decay corrected to end of
bombardment (EOB). The radiochemical purity was >99%, and the specific activity at EOB was 370-1110 GBq/mol with a total 
synthesis time of ~40-minutes from EOB. 
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Alzheimer‟s disease (AD) is a dominant public health 
problem because of increasing life expectancy and no 
reliable disease-modifying therapies at present.
1-3
Currently, the cause of AD remains unclear and no any 
effective strategy is approved for preventing, curing and 
slowing the progress of AD.
4-6
 To discover more
effective treatments, a reliable diagnostic tool is really 
needed.
7
 Neuroimaging of AD is one of the most active
as well as most challenging areas in neuroscience.
8
Advanced biomedical imaging technique positron 
emission tomography (PET) is a promising modality for 
AD, and significant advances have occurred in this field 
of molecular imaging.
9
 The development of PET
imaging probes for in vivo detection of Alzheimer‟s 
brains is critical for early and accurate diagnosis and for 
the successful discovery of disease-modifying 
therapies.
10-12
 Aggregated -amyloid plaques (A) and
tau protein are two major biomarkers for AD.
13,14 
A
PET tracers have been well-developed, and the 
representative radiopharmaceuticals include [
11
C]PIB
15
and [
18
F]Amyvid (formerly known as [
18
F]AV-45),
16
 as
displayed in Figure 1. The success and limitations of A 
imaging with [
11
C]PIB and [
18
F]Amyvid have spurred
efforts worldwide to develop selective PET tau tracers, 
since A imaging with current tracers still lacks 
diagnostic accuracy and high degree of correlations 
between sensitivity/specificity and pathology of AD, 
and more and more evidences demonstrate that 
increased tau levels appear to correlate with clinical AD 
severity.
17
 Recently the researchers have been focusing
on tau imaging, several highly selective and specific 
PET tau tracers like [
18
F]T808 ([
18
F]AV-680),
[
18
F]T807 ([
18
F]AV-1451), [
11
C]PBB3, [
18
F]THK-5105
and [
18
F]THK-5117 (Figure 1) have been developed,
and promising clinical PET imaging results with these 
tracers have been reported.
18-24
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 To address local investigator needs for PET tau tracers, 
we decided to make our own material by following the 
literature methods. In our previous work, we have 
reported the synthesis of fluorine-18 labelled tracers 
[
18
F]T808 and [
18
F]T807.
25,26
 In this ongoing study, we 
present the synthesis of a carbon-11 labelled tracer 
[
11
C]PBB3. Carbon-11 tracers have a potential 
advantage of back-to-back same-day studies of 
pharmacological or behavioral challenges, since it can 
avoid movement of the study subject from the PET 
scanner and perform the repeat studies within 2-3 hours 
to explore the drug effects. The published and patented 
synthesis of the authentic standard PBB3, its TBS-
protected N-desmethyl-PBB3 precursor and target tracer 
[
11
C]PBB3 lacks synthetic detail, and the key steps gave 
poor yield and was difficult to reproduce in our hands. 
Therefore, we investigated alternate approaches and 
modifications based on the reported literature 
methods
22,27,28
 that eventually resulted in higher-yield 
synthesis of PBB3, N-desmethyl-PBB3, TBS-protected 
N-desmethyl-PBB3 and [
11
C]PBB3 starting from very 
beginning materials 5-bromo-2-nitropyridine, acrolein 
diethyl acetal, 6-methoxy-2-methylbenzothiazole, and 
diethylchlorophosphate. The synthesis presented here 
was superior to previous works or addressed more 
synthetic details to reveal and explain technical 
artifices. In this letter we provide the complete 
experiment procedures, yields, analytical details and 
new findings for the synthesis of PBB3 and [
11
C]PBB3 
from TBS-protected N-desmethyl-PBB3 via one-pot-
two-step approach, and first present a fully automated 
one-pot-one-step radiosynthesis of [
11
C]PBB3 from N-
desmethyl-PBB3 with relatively high radiochemical 
yields and shortened radiosynthesis time.   
 
 
Figure 1. Chemical structure of [11C]PIB, [18F]Amyvid ([18F]AV-45), 
[11C]PBB3, [18F]T808 ([18F]AV-680), [18F]T807 ([18F]AV-1451), 
[18F]THK-5105 and [18F]THK-5117. 
 
The synthesis of reference standard PBB3 (5-((1E,3E)-
4-(6-methylamino)pyridin-3-yl)buta-1,3-dien-1-
yl)benzo[d]thiazol-6-ol, 6) is shown in Scheme 1, 
according to the patent method
28
 with modifications. 
The core structure diaryldiene 3 was achieved in 42% 
yield by Wittig-Horner reaction of aldehyde 1 and 
diethyl phosphonate 2 in the presence of NaH in 
THF.
29,30
 Cinnamaldehyde derivative 1 was prepared 
from 5-bromo-2-nitropyridine and acrolein diethyl 
acetal under Cacchi condition (K2CO3, tetra-n-butyl-
ammonium acetate (TBAA), KCl, DMF, 115 

C) with 
palladium (II) acetate as catalyst in an Ace pressure 
tube.
31-33
 The use of Ace pressure tube improved the 
yield of compound 1 from 12% to 30%. Coupling 
diethylchlorophosphate with 6-methoxy-2-
methylbenzothiazole in the presence of lithium 
diisopropylamide (LDA), that was freshly prepared in 
one-pot, produced diethyl phosphonate derivative 2 in 
67% yield.
34,35
 The nitro group of compound 3 was 
reduced with iron in acidic ethanol to yield amine 4 in 
28% yield. Reduction with SnCl2 in EtOH or acidic 
MeOH was less effective. Instead of N-
monomethylation of compound 4 with CH3I in the 
presence of NaH in DMF (14% yield), N-monomethyl 
derivative 5 was obtained by condensation with 
paraformaldehyde in the presence of NaOMe, followed 
by reduction with sodium borohydride in MeOH with a 
moderate yield (42%).
36
 Desmethylation of compound 5 
with BBr3 in CH2Cl2 afforded 6 in 69% yield. 
 
 
Scheme 1. Synthesis of PBB3 (6). 
 
The synthesis of precursors N-desmethyl-PBB3 (2-
((1E,3E)-4-(6-aminopyridin-3-yl)buta-1,3-dien-1-
yl)benzo[d]thiazol-6-ol, 7) and TBS-protected N-
desmethyl-PBB3 (5-((1E,3E)-4-(6-((tert-
butyldimethylsilyl)oxy)benzo[d]thiazol-2-yl)buta-1,3-
dien-1-yl)pyridin-2-amine, 8)  is outlined in Scheme 2, 
according to the patent method
28
 with modifications. 
 The methoxyl group of compound 4 was desmethylated 
with BBr3 in CH2Cl2 to provide phenol 7 in 71% yield, 
and its free hydroxyl group was protected with tert-
butyldimethylsilyl (TBS) group by reaction with tert-
butyldimethylsilyl chloride (TBSCl) in the presence of 
4-N,N-(dimethylamino)pyridine (DMAP) in DMF to 
afford TSB-protected precursor 8 in 33% yield. 
 
 
Scheme 2. Synthesis of N-desmethyl-PBB3 (7) and TBS-protected N-
desmethyl-PBB3 (8).  
 
Synthesis of [
11
C]PBB3 (5-((1E,3E)-4-(6-
[
11
C]methylamino)pyridin-3-yl)buta-1,3-dien-1-
yl)benzo[d]thiazol-6-ol, [
11
C]6) via TBS-protected N-
desmethyl-PBB3 (8) precursor is presented in Scheme 
3. The precursor 8 underwent N-[
11
C]methylation
37-40 
using the reactive [
11
C]methylating agent [
11
C]methyl 
triflate ([
11
C]CH3OTf)
41,42 
in dimethyl sulfoxide 
(DMSO) at 100 °C under basic condition (KOH) to give 
a radiolabeled intermediate TBS-protected [
11
C]PBB3.  
Without isolation, this was followed by a quick 
deprotection reaction using H2O to provide the target 
tracer [
11
C]PBB3. The radiolabeling mixture was 
isolated by semi-preparative reverse-phase (RP) high 
performance liquid chromatography (HPLC) with a C-
18 column,
 
and then concentrated by solid-phase 
extraction (SPE) with a disposable C-18 Plus Sep-Pak 
cartridge
43-45
 to produce the corresponding pure 
radiolabeled compound [
11
C]6 in 15-20%  
radiochemical yield, decay corrected to end of 
bombardment (EOB), based on [
11
C]CO2. This is a 1-
pot-2-step radiosynthesis. It is somewhat complicated 
with low radiochemical yield and long overall reaction 
time.   
 
 
Scheme 3. Synthesis of [11C]PBB3 ([11C]6) from TBS-protected N-
desmethyl-PBB3 (8). 
 
The chemical structure of [
11
C]PBB3 is somewhat 
similar to the chemical structure of [
11
C]PIB. The 
original radiosynthesis of [
11
C]PIB utilized the hydroxyl 
group protected precursor for carbon-11 labeling at 
amino group, followed by deprotection.
46
 Later a rapid 
one-step radiosynthesis of [
11
C]PIB using unprotected 
precursor for direct radiolabeling was developed,
47,48
 
which has become a popular radiosynthesis method for 
[
11
C]PIB production in PET radiochemistry facilities. 
Based on [
11
C]PIB radiosynthesis methodology, we 
developed 1-pot-1-step radiosynthesis for [
11
C]PBB3 
for the first time. 
 
Synthesis of [
11
C]PBB3 via N-desmethyl-PBB3 (7) 
precursor is outlined in Scheme 4. The precursor 7 was 
labeled by [
11
C]CH3OTf
 
through N-[
11
C]methylation
 
in 
acetone at 80 °C under neutral condition to directly give 
the target tracer. The radiolabeling mixture was isolated 
by RP-HPLC combined with SPE to produce the 
corresponding pure radiolabeled compound [
11
C]6 in 
20-25% decay-corrected radiochemical yield. This is a 
1-pot-1-step radiosynthesis with higher radiochemical 
yield and shorter overall synthesis time. No protection 
of 6-hydroxy group is required, greatly simplifying the 
synthetic method. 
 
 
Scheme 4. Synthesis of [11C]PBB3 ([11C]6) from N-desmethyl-PBB3 (7). 
 
Our approach employed more reactive [
11
C]CH3OTf, 
instead of commonly used [
11
C]methyl iodide 
([
11
C]CH3I),
49
 in N-[
11
C]methylation of the amino, and 
thus the radiochemical yield of [
11
C]6 was relatively 
high in both radiosynthesis approaches using protected 
and unprotected precursors. It is important to note that 
the strong base KOH at high reaction temperature 
(forcing conditions) would help the N-[
11
C]methylation 
of protected precursor 8, and significantly increase the 
radiochemical yield of [
11
C]6. However, for the 
unprotected precursor 7, it is needed to conduct the N-
[
11
C]methylation of the amino under mildly neutral 
condition, since the unprotected hydroxyl group in the 
precursor will be [
11
C]methylated with [
11
C]CH3OTf 
first under basic condition at high reaction temperature. 
Only a relatively small amount of the precursor (0.3-0.5 
mg) was used for radiolabeling, instead of more 
commonly used amount of the precursor (0.9-1.1 mg) in 
the literature,
27
 which improved the chemical purity of 
the final tracer solution. Furthermore, addition of water 
to quench the radiolabeling reaction and to dilute the 
radiolabeling mixture prior to the injection onto the 
semi-preparative HPLC column for purification, gave 
better separation of [
11
C]6 from its protected or 
unprotected precursor (8 or 7).  
 
The radiosynthesis was performed in a home-built 
automated multi-purpose [
11
C]-radiosynthesis 
module.
50-52
 This radiosynthesis module facilitated the 
overall design of the reaction, purification and 
 reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. In addition, 
the module is designed to allow in-process measurement 
of [
11
C]-tracer specific activity (SA, GBq/mol at EOB) 
using a radiation detector at the outlet of the HPLC-
portion of the system. For the reported syntheses, 
product SA was in a range of 370-1110 GBq/mol at 
EOB. The factors that affect the EOB SA significantly 
to lead to such a wide range from 370 to 1110 
GBq/mol are mainly from two parts: (1) carrier from 
the [
11
C]-target, and (2) carrier from the [
11
C]-
radiosynthesis unit.
53
 We have optimized the [
11
C] gas 
irradiation target system and the [
11
C]-radiosynthesis 
unit to eliminate 
12
C carrier-added as much as possible 
and to reach the high end of the SA. To help produce 
high SA [
11
C]CO2, we usually do 10-minute target pre-
burn for 2-3 times, with the same beam current, prior to 
the actual production run. These pre-burn warm up the 
cyclotron target and eliminate significant amount of 
12
C 
carrier in the cyclotron‟s [
11
C] gas target. We use an 
Eckert & Ziegler Modular Lab C-11 Methyl 
Iodide/Triflate module to produce [
11
C]CH3OTf, 
convenient gas phase bromination of [
11
C]methane, and 
production of [
11
C]CH3OTf. This „dry‟ method, using 
Br2 to generate a [
11
C]CH3Br intermediate, differs from 
other „dry‟ methods using I2 and „wet‟ methods using 
LiAlH4 and HI, and seems to help minimize 
introduction of additional 
12
C carrier after [
11
C]CO2 
production.
42
 To further help produce high SA 
[
11
C]CH3OTf, we usually do 2 “test loop” procedures 
when we set up the module for the actual [
11
C]CH3OTf 
production run. These procedures avoid any leak in the 
module to introduce additional 
12
C carrier and eliminate 
significant amount of original 
12
C carrier accumulated 
in the [
11
C]CH3OTf production system.      
 
The 1-pot-1-step radiosynthesis via N-desmethyl-PBB3 
is a non-specific synthesis route, and 1-pot-2-step 
radiosynthesis via TBS-protected N-desmethyl-PBB3 is 
a specific synthesis route. The non-specific route 
required lower reaction temperature, shorter reaction 
time, and shorter overall synthesis time. Consequently it 
gave higher radiochemical yield. In addition, it is easier 
to synthesize the precursor without TBS group than 
with TBS group. This route is somewhat simpler to 
implement as it avoids adding a deprotection step. In 
comparison with these two radiosynthesis approaches, 
the non-specific route is identified as a more appropriate 
route for future applications.   
  
Chemical purity and radiochemical purity were 
determined by analytical HPLC.
54
 The chemical purity 
of the precursors and reference standard was >90%. The 
radiochemical purity of the target tracer was >99% 
determined by radio-HPLC through -ray (PIN diode) 
flow detector, and the chemical purity of the target 
tracer was >90% determined by reversed-phase HPLC 
through UV flow detector.   
 
The experimental details and characterization data for 
compounds 1-8 and for the tracer [
11
C]6 are given.
55 
 
 
In summary, synthetic routes with moderate to high or 
improved yields have been developed to produce the 
precursors TBS-protected N-desmethyl-PBB3 and N-
desmethyl-PBB3, the reference standard PBB3, and the 
target PET radiotracer [
11
C]PBB3. The radiosynthesis 
employed [
11
C]CH3OTf for N-[
11
C]methylation at the 
nitrogen position of the amine precursors, followed by 
product purification and isolation by a semi-preparative 
RP HPLC combined with SPE. The desired [
11
C]PBB3 
was obtained in high radiochemical yield, radiochemical 
purity and chemical purity, with a reasonably short 
overall synthesis time, and high specific activity. This 
will facilitate studies to evaluate [
11
C]PBB3 as a PET 
AD tau tracer in animals and humans.  
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1
H and 
13
C NMR spectra were recorded
on a Bruker Avance II 500 MHz NMR Fourier
transform spectrometer at 500 and 125 MHz,
respectively. Chemical shifts (δ) are reported in parts
per million (ppm) relative to an internal standard
tetramethylsilane (TMS,  0.0) (1H NMR) and to the
solvent signal (
13
C NMR), and coupling constants (J)
are reported in hertz (Hz). Liquid chromatography-
mass spectra (LC-MS) analysis was performed on an
Agilent system, consisting of an 1100 series HPLC
connected to a diode array detector and a 1946D mass
spectrometer configured for positive-ion/negative-ion
electrospray ionization. Chromatographic solvent
proportions are indicated as volume: volume ratio.
Thin-layer chromatography (TLC) was run using
Analtech silica gel GF uniplates (5  10 cm2).  Plates
were visualized under UV light. Preparative TLC was
run using Analtech silica gel UV254 plates (20  20
cm
2
). Normal phase flash column chromatography
was carried out on EM Science silica gel 60 (230-400
mesh) with a forced flow of the indicated solvent
system in the proportions described below. All
moisture- and air-sensitive reactions were performed
under a positive pressure of nitrogen maintained by a
direct line from a nitrogen source. Analytical RP
HPLC was performed using a Prodigy (Phenomenex)
5 m C-18 column, 4.6  250 mm; mobile phase 40%
CH3CN/60% 20 mM H3PO4; flow rate 1.0 mL/min;
and UV (379 nm) and -ray (PIN diode) flow
detectors. Semi-preparative RP HPLC was performed
using a Gemini ODS (Phenomenex) 5 m C-18
column, 10  250 mm; mobile phase 22%
CH3CN/78% 20 mM NH4OH; 8.0 mL/min flow rate;
UV (379 nm) and -ray (PIN diode) flow detectors.
C18 Plus Sep-Pak cartridges were obtained from
Waters Corporation (Milford, MA).  Sterile Millex-FG
0.2 m filter units were obtained from Millipore
Corporation (Bedford, MA).
(b). (E)-3-(6-Nitropyridin-3-yl)acrylaldehyde (1): A
suspension of 5-bromo-2-nitropyridine (1.50 g, 7.4
mmol), acrolein diethyl acetal (3.36 mL, 22.0 mmol),
K2CO3 (1.53 g, 11.1 mmol), TBAA (4.50 g, 14.9
mmol), KCl (552 mg, 7.4 mmol), palladium (II)
acetate (670 mg, 2.98 mmol), and DMF (30 mL) in an
Ace pressure tube under N2 atmosphere was stirred at
115 °C overnight.  The reaction mixture was cooled,
filtered through Celite, and washed with EtOAC.  The
combined filtrate was cooled in an ice bath, and an 
aqueous 2 N HCl (120 mL) was added slowly. After 
the mixture was stirred at room temperature (RT) for 
30 min, it was poured into ice-water and neutralized 
with saturated aqueous NaHCO3. The mixture was 
extracted with EtOAc, the combined organic layer was 
washed with brine, dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The above reaction 
and work up was repeated 10 times. The combined 
crude product was purified by column 
chromatography with CH2Cl2/MeOH (from 250:3 to 
250:5) as eluent to afford compound 1 as a pale 
yellow solid (4.01 g, 30%). 
1
H NMR (CDCl3):  9.80
(d, J = 7.0 Hz, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.33 (d, J 
= 8.5 Hz, 1H), 8.23 (dd, J = 4.0, 8.5 Hz, 1H), 7.58 (d, 
J = 16.0 Hz, 1H), 6.88 (dd, J = 7.0, 16.0 Hz, 1H). 
(c). Diethyl ((6-methoxybenzo[d]thiazol-2-
yl)methyl)phosphonate (2): To a stirred solution of  n-
BuLi (2.5 M in hexanes, 25 mL, 62.5 mmol)) in 
anhydrous THF (25 mL) was added diisopropylamine 
(8.76 mL, 62.5 mmol) at -78 °C under N2 atompshere. 
The mixture was stirred at this temperature for 30 min. 
To this LDA mixture, a solution of 6-methoxy-2-
methylbenzothiazole (5.00 g, 27.9 mmol) in 
anhydrous THF (40 mL) was added dropwise and the 
resulting reddish solution was stirred 30 min at -78 
°C. Then, a diethylchlorophosphate (4.44 mL, 30.7 
mmol) solution in anhydrous THF (20 mL) was added 
dropwise. After the reaction mixture was stirred 10 
min at -78 °C, it was allowed to warm up to RT and 
stirred at RT for 1 h.   The reaction was quenched with 
aqueous 1 N NH4Cl (100 mL), and the mixture was 
extracted with CHCl3. The combined organic layer 
was washed with aqueous 2% Na2CO3, brine and dried 
over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified by column 
chromatography with CH2Cl2/MeOH (250:5) as eluent 
to afford compound 2 as an orange oil (5.91 g, 67%). 
1
H NMR (CDCl3):  7.79 (d, J = 9.0 Hz, 1H), 7.22 (d, 
J = 2.5 Hz, 1H), 6.98 (dd, J = 2.5, 9.0 Hz, 1H), 4.06 
(quin, J = 2.0 Hz, 4H), 3.78 (s, 3H), 3.62 (d, J = 21.5 
Hz, 2H), 1.24 (t, J = 2.0 Hz, 6H). 
(d). 6-Methoxy-2-((1E,3E)-4-(6-nitropyridin-3-
yl)buta-1,3-dien-1-yl)benzo[d]thiazole (3): To a 
stirred solution of compound 2 (4.41 g, 14.0 mmol) in 
anhydrous THF (50 mL) was added NaH (60% 
dispersion in mineral oil, 780 mg, 19.5 mmol) at 0 °C 
under N2 atmosphere. After the mixture was allowed 
to warm up to RT and stirred at RT for 30 min, 
compound 1 (2.30 g, 12.9 mmol) was added. The 
reaction mixture was stirred at RT overnight, and it 
was cooled in an ice bath.  Saturated aqueous NH4Cl 
(16 mL) was added and stirred at 0
 °C. The sticky 
solid was decanted, washed with water, and dried in 
vacuo. The crude solid product was suspended in 
toluene, and washed with toluene and CH2Cl2 to 
afford compound 3 as an orange solid (1.82 g, 42%). 
1
H NMR (DMSO-d6):  8.80 (s, 1H), 8.37-8.31 (m, 
 2H), 7.87 (d, J = 8.0 Hz, 1H), 7.67 (s, 1H), 7.60-7.55 
(m, 1H), 7.42-7.37 (m, 1H), 7.17 (d, J = 15.5 Hz, 2H), 
7.12 (d, J = 8.0 Hz, 1H), 3.85 (s, 3H). 
(e). 5-((1E,3E)-4-(6-Methoxybenzo[d]thiazol-2-
yl)buta-1,3-dien-1-yl)pyridin-2-amine (4): To a stirred 
mixture of compound 3 (1.47 g, 4.34 mmol), iron 
powder (1.14 g, 20.4 mmol) and HOAc (28 mL) in 
EtOH (280 mL) was added aqueous 12 N HCl (6 mL) 
dropwise. After the reaction mixture was stirred at RT 
overnight, it was cooled in an ice bath, neutralized 
with aqueous 6 N NaOH, and filtered to remove the 
precipitate. MeOH was added to the precipitate, and 
the mixture was stirred and filtered. The filtrates were 
combined. After the solvent was evaporated in vacuo, 
the crude product was purified by column 
chromatography with CHCl3/MeOH (250:10) as 
eluent to afford compound 4 as a yellow solid (372 
mg, 28%). 
1
H NMR (CDCl3):  8.12 (d, J = 2.5 Hz, 
1H), 7.84 (d, J = 9.0 Hz, 1H), 7.64 (dd, J = 2.5, 8.5 
Hz, 1H), 7.29 (d, J = 2.5 Hz, 1H), 7.20 (dd, J = 10.0, 
15.5 Hz, 1H), 7.05 (dd, J = 2.5, 9.0 Hz, 1H), 6.85 (d, J 
= 15.0 Hz, 1H), 6.80 (dd, J = 10.0, 15.5 Hz, 1H), 6.72 
(d, J = 15.5 Hz, 1H), 6.51 (d, J = 9.0 Hz, 1H), 4.63 (s, 
2H), 3.88 (s, 3H). LC-MS (ESI, m/z): Calcd for 
C17H16N3OS ([M+H]
+
) 310.1; found 310.1.  
(f). 5-((1E,3E)-4-(6-Methoxybenzo[d]thiazol-2-
yl)buta-1,3-dien-1-yl)-N-methylpyridin-2-amine (5): 
To a stirred solution of compound 4 (50 mg, 0.16 
mmol) in anhydrous MeOH (6 mL) was added 
NaOMe (81 mg, 1.5 mmol), and followed by 
paraformaldehyde (48 mg, 1.6 mmol). After the 
reaction mixture was heated and refluxed for 3 h, it 
was cooled to 0 °C. Sodium borohydride (121 mg, 3.2 
mmol) was added portionwise. The mixture was 
heated and refluxed for another 1 h, then cooled in an 
ice bath. Water was added, and the mixture was 
extracted with CH2Cl2. The combined organic layer 
was washed with brine, dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude product 
was purified by preparative TLC plate with 
CH2Cl2/MeOH (100:5) as eluent to afford compound 5 
as a yellow solid (22 mg, 42%). 
1
H NMR (DMSO-d6): 
 8.15 (d, J = 2.5 Hz, 1H), 7.84 (d, J = 9.0 Hz, 1H), 
7.74 (dd, J = 2.0, 8.5 Hz, 1H), 7.67 (d, J = 2.5 Hz, 
1H), 7.32 (dd, J = 10.5, 15.5 Hz, 1H), 7.12 (dd, J = 
2.5, 9.0 Hz, 1H), 6.98-6.89 (m, 4H), 6.54 (d, J = 9.0 
Hz, 1H), 3.88 (s, 3H), 2.86 (d, J = 4.5 Hz, 3H). LC-
MS (ESI, m/z): Calcd for C18H18N3OS ([M+H]
+
) 
324.1; found 324.0. 
(g). 5-((1E,3E)-4-(6-Methylamino)pyridin-3-yl)buta-
1,3-dien-1-yl)benzo[d]thiazol-6-ol (PBB3, 6): To a 
stirred suspension of compound 5 (20 mg, 0.062 
mmol) in anhydrous CH2Cl2 (1 mL) was added BBr3 
(1.0 M solution in CH2Cl2, 0.4 mL, 0.4 mmol) 
dropwise at -78
 °C under N2 atmosphere. After the 
mixture was allowed to warm up to room temperature 
and stirred at RT overnight, the reaction was quenched 
with water in an ice bath, and it was neutralized with 
aqueous 1 N NaOH solution. The precipitate was 
collected by filtration, washed with water and dried in 
vacuo. The crude product was purified by preparative 
TLC plate with CH2Cl2/MeOH (100:5) as eluent to 
afford compound 6 as a yellow solid (13 mg, 69%). 
1
H 
NMR (DMSO-d6):  9.99 (br s, 1H), 8.10 (d, J = 1.5 
Hz, 1H), 7.72-7.68 (m, 2H), 7.33 (d, J = 2.0 Hz, 1H), 
7.22 (dd, J = 10.5, 15.5 Hz, 1H), 6.98-6.91 (m, 3H), 
6.84 (dd, J = 4.5, 15.5 Hz, 2H), 6.49 (d, J = 9.0 Hz, 
1H), 2.81 (d, J = 4.5 Hz, 3H).
 13
C NMR (DMSO-d6): 
162.9, 159.2, 155.8, 148.5, 147.1, 137.6, 135.3, 134.9, 
133.4, 123.3, 122.9, 122.8, 120.5, 115.8, 106.6, 30.6, 
27.9. LC-MS (ESI, m/z): Calcd for C17H16N3OS 
([M+H]
+
) 310.1; found 310.1.  
(h). 2-((1E,3E)-4-(6-Aminopyridin-3-yl)buta-1,3-dien-
1-yl)benzo[d]thiazol-6-ol (N-desmethyl-PBB3, 7): To 
a stirred suspension of compound 4 (166 mg, 0.54 
mmol) in anhydrous CH2Cl2 (3 mL) was added BBr3 
(1.0 M solution in CH2Cl2, 3 mL, 3.0 mmol) dropwise 
at -78
 °C under N2 atmosphere. After the mixture was 
allowed to warm up to RT and stirred at RT overnight, 
the reaction was quenched with water in an ice bath. 
The precipitate was collected by filtration, and washed 
with aqueous 5% NaHCO3 and water. The solid was 
dried in vacuo to afford compound 7 as a yellow solid 
(113 mg, 71%). 
1
H NMR (DMSO-d6):  9.85 (s, 1H), 
8.03 (d, J = 2.0 Hz, 1H), 7.71-7.67 (m, 2H), 7.33 (d, J 
= 2.5 Hz, 1H), 7.22 (dd, J = 10.5, 15.5 Hz, 1H), 6.96-
6.89 (m, 2H), 6.84 (d, J = 15.0 Hz, 2H), 6.48 (d, J = 
8.5 Hz, 1H), 6.35 (br s, 2H). LC-MS (ESI, m/z): Calcd 
for C16H14N3OS ([M+H]
+
) 296.1; found 296.0. 
(j). 5-((1E,3E)-4-(6-((tert-
Butyldimethylsilyl)oxy)benzo[d]thiazol-2-yl)buta-1,3-
dien-1-yl)pyridin-2-amine (TBS-protected N-
desmethyl-PBB3, 8): To a stirred solution of 
compound 7 (30 mg, 0.10 mmol) and DMAP (37 mg, 
0.31 mmol) in DMF (1 mL) was added TBSCl (25 
mg, 0.16 mmol). After the reaction mixture was stirred 
at RT overnight, it was quenched with water. The 
mixture was extracted with EtOAC. The combined 
organic layer was washed with brine, dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by preparative TLC 
plate with CHCl3/MeOH (100:7) as eluent to afford 
compound 8 as a yellow solid (14 mg, 33%). 
1
H NMR 
(DMSO-d6):  8.04 (d, J = 2.5 Hz, 1H), 7.78 (d, J = 
9.0 Hz, 1H), 7.69 (dd, J = 2.5, 8.5 Hz, 1H), 7.52 (d, J 
= 2.5 Hz, 1H), 7.28 (dd, J = 10.0, 15.0 Hz, 1H), 6.99 
(dd, J = 2.5, 8.5 Hz, 1H), 6.96-6.86 (m, 3H), 6.48 (d, J 
= 9.0 Hz, 1H), 6.37 (br s, 2H), 0.97 (s, 9H), 0.23 (s, 
6H). LC-MS (ESI, m/z): Calcd for C22H28N3OSSi 
([M+H]
+
) 410.2; found 410.1. 
(k) 5-((1E,3E)-4-(6-[
11
C]Methylamino)pyridin-3-
yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-ol 
([
11
C]PBB3, [
11
C]6): Method A (from TBS-protected 
N-desmethyl-PBB3, 8). [
11
C]CO2 was produced by the 
14
N(p,)11C nuclear reaction in the small volume (9.5 
cm
3
) aluminum gas target provided with the Siemens 
RDS-111 Eclipse cyclotron. The target gas consisted 
of 1% oxygen in nitrogen purchased as a specialty gas 
from Praxair, Indianapolis, IN. Typical irradiations 
used for the development were 55 A beam current 
and 30 min on target.  The production run produced 
approximately 45.5 GBq of [
11
C]CO2 at EOB. In a
small reaction vial (5 mL), the precursor 8 (0.3-0.5 
mg) was dissolved in DMSO (500 L).  To this 
solution was added dry KOH (3 mg). No carrier-added 
(high specific activity) [
11
C]CH3OTf that was
produced by the gas-phase production method
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 from 
[
11
C]CO2 through [
11
C]CH4 and [
11
C]CH3Br with
silver triflate (AgOTf) column was passed into the 
reaction vial at RT, until radioactivity reached a 
maximum (~2 min), and then the reaction vial was 
isolated and heated at 100 

C for 5 min to form a 
radiolabeled intermediate TBS-protected [
11
C]PBB3. 
Then, water (500 L) was introduced to the reaction 
vial. The reaction mixture was sealed and heated at 80 
°C for 3 min. The contents of the reaction vial were 
diluted with water (1 mL), and injected onto the semi-
preparative RP HPLC column with 3 mL injection 
loop for purification. The product fraction was 
collected in a recovery vial containing 30 mL water. 
The diluted tracer solution was then passed through a 
C-18 Sep-Pak Plus cartridge, and washed with water 
(5 mL × 4).  The cartridge was eluted with EtOH (1 
mL  2), followed by 10 mL saline, to release [11C]6. 
The eluted product was then sterile-filtered through a 
sterile vented Millex-FG 0.2 m filter, and collected 
into a sterile vial. Total radioactivity (1.7-2.3 GBq) 
was assayed and total volume (10-11 mL) was noted 
for tracer dose dispensing, which was diluted with 
additional saline, since the ethanol concentration in 
the tracer is required to be <10% in real clinical 
setting. The overall synthesis, purification and 
formulation time was ~40 min from EOB.  Retention 
times in the analytical HPLC system were: tR 8 = 8.83 
min, tR 6 = 6.56 min, and tR [
11
C]6 = 6.64 min.
Retention times in the semi-preparative HPLC system 
were: tR 8 = 15.43 min, tR 6 = 11.01 min, and tR [
11
C]6
= 11.15 min. The radiochemical yield of [
11
C]6 was 
15-20% decay corrected to EOB, based on [
11
C]CO2.
Method B (from N-desmethyl-PBB3, 7). The precursor 
7 (0.3-0.5 mg) was dissolved in acetone (500 L) in a 
5-mL V-vial. [
11
C]CH3OTf was passed into the
reaction vial at RT until radioactivity reached a 
maximum (~2 min), and then the reaction vial was 
isolated and heated at 80 °C for 5 min. The contents of 
the reaction vial were diluted with water (1 mL), and 
injected onto the semi-preparative HPLC column with 
3 mL injection loop for purification. The purification 
and formulation procedures were same with Method 
A. The overall synthesis, purification and formulation 
time was ~35 min from EOB. Retention times in the 
analytical HPLC system were: tR 7 = 4.53 min, tR 6 = 
6.56 min, and tR [
11
C]6 = 6.64 min. Retention times in
the semi-preparative HPLC system were: tR 7 = 7.66 
min, tR 6 = 11.01 min, and tR [
11
C]6 = 11.15 min. The
decay corrected radiochemical yields were 20-25%. 
